Literature DB >> 3659571

Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.

Y Tokuma1, T Fujiwara, H Noguchi.   

Abstract

The plasma levels of (+)- and (-)-nilvadipine 1 h after an oral dose of racemic (+)-nilvadipine 4 mg in sixteen healthy volunteers were studied to find the extent of variation between (+)- and (-)-nilvadipine plasma levels. Additionally the pharmacokinetic profiles of the enantiomers in the plasma up to 12 h after dosing were examined in three subjects. The plasma levels of the (+)- and (-)-nilvadipine in the three subjects peaked at 0.5-1 h, and the maximum concentration and the area under the plasma concentration-time curve of the more potent (+)-enantiomer were 2.38-3.18 and 2.27-3.10 times, respectively, higher than those of its optical antipode. The half-lives of the enantiomers were mostly similar. In the sixteen subjects, the ratio between (+)- and (-)-nilvadipine levels 1 h after dosing with racemic (+)-nilvadipine were from 1.77 to 3.65.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3659571

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  3 in total

1.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Authors:  T Iwaoka; N Inotsume; J Inoue; S Naomi; Y Okamoto; S Higuchi; M Nakano; T Umeda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.

Authors:  P A Soons; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.